Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones Loom

Vertex Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Vertex expects a Nov. 30 U.S. decision on povetacicept for IgA nephropathy, pursuing accelerated approval. Interim data showed a 52% reduction in proteinuria at 36 weeks; the drug is proposed for monthly at-home dosing, though the final label is up to regulators.
  • Vertex anticipates several pipeline milestones through 2027, including first-quarter 2027 interim Phase 3 results for inaxaplin in APOL1-mediated kidney disease, plus readouts in myotonic dystrophy, myasthenia gravis and diabetic peripheral neuropathy.
  • The company expects non-CF product revenue to exceed its previously discussed $500 million 2026 estimate after adding PALSONIFY, with further growth expected in 2027 while its cystic fibrosis business remains solid.
  • Five stocks to consider instead of Vertex Pharmaceuticals.

Vertex Pharmaceuticals NASDAQ: VRTX is approaching a Nov. 30 U.S. regulatory decision for its kidney disease drug povetacicept, with a series of clinical readouts expected through 2027 as the company seeks to expand beyond its cystic fibrosis business.

Speaking at a Jefferies fireside chat in London, Susie Lisa, Vertex’s senior vice president of investor relations, said the company remains confident in its preparations for the decision on povetacicept in immunoglobulin A nephropathy, or IgAN. She also outlined upcoming studies in kidney disease, pain and myotonic dystrophy.

Vertex has previously discussed more than $500 million in 2026 revenue from its non-cystic fibrosis products JOURNAVX and CASGEVY. Lisa said PALSONIFY, added through the recent acquisition of Crinetics, would take the total above that level. The company expects further non-cystic fibrosis growth in 2027 while maintaining a solid outlook for its cystic fibrosis franchise, she said.

Povetacicept Decision Approaches

Lisa said regulatory activities, including inspections, have occurred on the expected schedule, giving Vertex “high visibility and confidence” in the Nov. 30 decision date. The company is seeking accelerated approval in the U.S. and has also filed in Saudi Arabia, she said.

Vertex believes povetacicept could offer leading efficacy and convenience in its class, Lisa said. At an interim analysis, the drug produced a 52% reduction in proteinuria, a measure of protein in urine, at 36 weeks. She also pointed to its proposed once-every-four-weeks dosing with an at-home auto-injector.

Lisa said the company expects a label consistent with the class and without a requirement to monitor immunoglobulin G, or IgG. She cited a 0.5% rate of serious infections in the interim analysis, the same in the treatment and placebo groups. The ultimate label remains subject to the regulatory decision.

Two-year kidney function data will be important for markets including Europe and Asia, where Lisa said regulators require that endpoint. Vertex estimates that about 160,000 people in the U.S. have biopsy-confirmed IgAN, with a similar-sized population in Europe and an estimated 1.5 million to 1.6 million globally. The company has partnered with Ono Pharma and Zai Lab for commercialization in parts of Asia.

Although two competing therapies have already launched, Lisa said Vertex does not view being third to market or launching without long-term kidney function data as inherent obstacles. She said the initial U.S. focus would be patients who have not previously received treatment, with potential for switching later.

Inaxaplin and Other 2027 Readouts

Vertex expects first-quarter 2027 interim Phase 3 results from AMPLITUDE, its study of inaxaplin in APOL1-mediated kidney disease. If the results are positive, the company could seek accelerated approval, Lisa said.

She stressed that Vertex needs to demonstrate a difference between inaxaplin and placebo in the slope of estimated glomerular filtration rate, or eGFR, a measure of kidney function, to file for accelerated approval. The study also measures proteinuria.

Lisa said earlier data supported the company’s optimism, including a 47.6% reduction in proteinuria at 13 weeks in an initial Phase 2 study. A separate study, AMPLIFIED, showed a 44% reduction at 13 weeks in a group with more modest proteinuria. “We need to see the data,” she added.

Other expected milestones include Phase 2 proof-of-concept data by the end of 2026 for Vertex’s myotonic dystrophy type 1 compound, and initial results in the first half of 2027 from a povetacicept study in myasthenia gravis. Vertex also expects results around mid-2027 from two Phase 3 studies of suzetrigine in diabetic peripheral neuropathy, Lisa said.

Crinetics Drug Safety and Trial Timing

Manisha Pai, Vertex’s executive director of investor relations, said the company began evaluating Crinetics around January and viewed it as a fit with its focus on severe diseases with well-understood biology and specialty markets.

Asked about liver safety for atumelnant, a drug being studied in congenital adrenal hyperplasia, Pai said one liver event in Phase 2 could not definitively be ruled out as drug-related. The patient stopped treatment and the event resolved, she said. Pai added that there were no cases of Hy’s law, a marker used to assess potential severe drug-induced liver injury, and no additional liver events had been seen in the ongoing open-label extension.

Vertex expects to present fuller extension data at a medical meeting in 2027. Enrollment in the ongoing Phase 3 study is expected to finish in the first quarter of 2027, with a possible data readout in late 2027 or early 2028 following 32 weeks of dosing, Pai said.

About Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex's CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?

Before you consider Vertex Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.

While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines